Humacyte (HUMA) Net Equity Issued and Repurchased (2020 - 2026)

Humacyte (HUMA) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $4.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased rose 85.8% year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at -$39.9 million (down 1694.2% YoY), while the FY2024 annual figure was $43.4 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased advanced to $4.6 million in Q1 2026 per HUMA's latest filing, from -$47.0 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $43.4 million in Q1 2024 and bottomed at -$47.0 million in Q4 2025.
• Historically, Net Equity Issued and Repurchased has averaged $863000.0 across 3 years, with a median of $2.5 million in 2025.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 105.76% in 2025 and fell as far as 94.24% in 2025.
• Humacyte's Net Equity Issued and Repurchased stood at $43.4 million in 2024, then slumped by 208.3% to -$47.0 million in 2025, then surged by 109.88% to $4.6 million in 2026.
• Business Quant data shows HUMA's Net Equity Issued and Repurchased at $4.6 million in Q1 2026, -$47.0 million in Q4 2025, and $2.5 million in Q2 2025.